Palonosetron Available in Prefilled Syringe for Chemotherapy-Induced Nausea, Vomiting

The prefilled syringe is part of the Company's Simplist portfolio and is the first FDA-approved prefilled delivery version of palonosetron hydrochloride (HCI) to become available.

Palonosetron hydrochloride is now available in a ready-to-administer prefilled syringe. The Simplist Palonosetron Hydrochloride Injection is manufactured by Fresenius Kabi and is part of the Company’s Simplist portfolio. This is the first FDA-approved prefilled delivery version of palonosetron HCI to become available. 

Palonosetron hydrochloride (HCI) is a serotonin-3 (5-HT3) receptor antagonist. It is indicated in adults for the prevention of acute nausea and vomiting due to initial and repeat courses of moderately and highly emetogenic chemotherapy and for prevention of delayed nausea and vomiting due to initial and repeat courses of moderately emetogenic chemotherapy. It is also indicated for the prevention of acute nausea and vomiting due to initial and repeat courses of emetogenic chemotherapy, including highly emetogenic cancer chemotherapy, in children 1 month–<17yrs. 

Related Articles

The product is supplied in a 0.25mg per 5mL dosage strength.

For more information visit Fresenius-Kabi.com.